AOL
MAIL
- You might also like:
- AOL Jobs,
- AOL Real Estate
- and More

Ticker

Advertisement Find a Broker - Visit the DailyFinance Broker Center

DJIA	12,454.83	-74.92	-0.60%
NASDAQ	2,837.53	-1.85	-0.07%
S&P 500	1,317.82	-2.86	-0.22%

Recent Quotes Watchlist My Portfolios

Add

$2.84 $0.02 (0.71%)

REAL-TIME: Last trade at 4:00 PM EDT on 05/25/12

AVANIR PHARMACEUTICALS

NASDAQ:AVNR

+ Add to Portfolio
+ Add to Alerts

Related Resources

Avanir Pharmaceuticals CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

5/17/2012 by Seeking Alpha

Avanir Pharmaceuticals' Presents at Deutsche Bank Securities Annual Health Care Conference (Transcript)

5/9/2012 by Seeking Alpha

Avanir Loss Widens in 2Q

5/9/2012 by Drug Discovery & Development

Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript

5/8/2012 by Seeking Alpha

Avanir takes bigger loss on Nuedexta sales costs

5/8/2012 by Bioscience Technology

Avanir Pharmaceuticals (AVNR) Misses Q2 Loss Views by 1c/Share

5/8/2012 by StreetInsider.com

Avanir Pharmaceuticals reports Q2 EPs (13c), consensus (12c)

5/8/2012 by Theflyonthewall.com

Avanir Pharmaceuticals FY Q2 Earnings Preview: Meet, Beat Or Miss?

5/4/2012 by Seeking Alpha

Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call

5/1/2012 by PR Newswire

American Academy of Neurology to host annual meeting

4/23/2012 by Theflyonthewall.com

8 Stocks Under $10 Moving Higher

4/19/2012 by TheStreet.com

Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting

4/17/2012 by PR Newswire

Science Vs. Hedge Funds: Influences On New Drug Approval Process

4/16/2012 by Seeking Alpha

Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference

4/10/2012 by PR Newswire

Applicability Of Short Squeezes Of 4 Pharma Stocks

3/30/2012 by Seeking Alpha

Obesity Drug Candidates' Parallels With Approval Process Of Other Drugs

3/23/2012 by Seeking Alpha

TREAT Act Poised to Revolutionize the Biotechnology Industry

3/22/2012 by Marketwire

Rohan Palekar rides in as Avanir CCO

3/20/2012 by Script World Pharmaceutical News - UK

Avanir (AVNR) Taps Medivation's (MDVN) Palekar as CCO

3/16/2012 by StreetInsider.com

Avanir Pharmaceuticals announces appointment of new Chief Commercial Officer

3/16/2012 by Theflyonthewall.com

Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer

3/16/2012 by PR Newswire

Cell Therapeutics and Avanir Pharmaceuticals Look to Make Headway in Strengthening Biotech Industry

3/12/2012 by Marketwire

Avanir Pharmaceuticals to Participate in Two Conferences in March

3/1/2012 by PR Newswire

Concert/Avanir deal could rake in $200M

3/1/2012 by Boston Business Journal - Boston MA

Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze

3/1/2012 by Seeking Alpha

Avanir gains rights to Concert's 'heavy' Nuedexta dextromethorphan

3/1/2012 by Script World Pharmaceutical News - UK

Concert Pharma deal with Avanir could top $200M

2/29/2012 by Boston Business Journal - Boston MA

Avanir's CEO Presents at Citi 2012 Global Health Care Conference - Transcript

2/29/2012 by Seeking Alpha

Avanir Pharmaceuticals, Concert announce license agreement

2/29/2012 by Theflyonthewall.com

3 Biotech Companies: 2 To Buy And 1 To Day Trade

2/28/2012 by Seeking Alpha

Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference

2/21/2012 by PR Newswire

Avanir Pharmaceuticals: Limelight On The Horizon

2/17/2012 by Seeking Alpha

Avanir Pharmaceuticals: The Perfect 2012 Stock For Cubs Fans

2/11/2012 by Seeking Alpha

Avanir Q1 net loss increases

2/10/2012 by Datamonitor

Avanir Pharmaceuticals Announces Publication Of Phase III Study Results Showing Efficacy And Safety Of AVP-923 In The Treatment Of Diabetic Neuropathic Pain

2/9/2012 by Biocompare

Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Good Nuedexta Trends Continues, Phase 2 Progress

2/8/2012 by StreetInsider.com

Avanir (AVNR) Reports Publication of Superior Results from AVP-923 Phase III Dosage Study

2/8/2012 by StreetInsider.com

Avanir Pharmaceuticals' AVP-923 for diabetis shows positive Phase III results

2/8/2012 by Theflyonthewall.com

Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain

2/8/2012 by PR Newswire

AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript

2/7/2012 by Seeking Alpha

See More Articles...

Get the latest AVNR stock information on the web. Get the latest stock quote and more - DailyFinance is your source for AVANIR PHARMACEUTICALS stock price.

BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
Analyst Recommendations provided by Midnight Trader, Inc. Company Conference Calls provided by Wall Street Horizon.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions.

Notices & Terms: Confirm all data with your broker before trading.

Questions or Comments? Please give feedback here.

© 2012 AOL Inc. All Rights Reserved.

AOL@Money © 2012 AOL Inc. All Rights Reserved.

WEB108 / 31.2518 ms